A new trading day began on Tuesday, with Edgewise Therapeutics Inc (NASDAQ: EWTX) stock price up 0.54% from the previous day of trading, before settling in for the closing price of $14.79. EWTX’s price has ranged from $10.60 to $38.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -20.24%. With a float of $73.98 million, this company’s outstanding shares have now reached $95.21 million.
The firm has a total of 110 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Edgewise Therapeutics Inc (EWTX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Edgewise Therapeutics Inc is 29.68%, while institutional ownership is 74.86%. The most recent insider transaction that took place on May 02 ’25, was worth 25,520. In this transaction Chief Scientific Officer of this company sold 1,551 shares at a rate of $16.45, taking the stock ownership to the 18,521 shares. Before that another transaction happened on May 02 ’25, when Company’s General Counsel sold 1,930 for $16.45, making the entire transaction worth $31,757. This insider now owns 6,531 shares in total.
Edgewise Therapeutics Inc (EWTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.14% during the next five years compared to -49.00% drop over the previous five years of trading.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Trading Performance Indicators
Here are Edgewise Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 20.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.91 in one year’s time.
Technical Analysis of Edgewise Therapeutics Inc (EWTX)
Analysing the last 5-days average volume posted by the [Edgewise Therapeutics Inc, EWTX], we can find that recorded value of 1.01 million was lower than the volume posted last year of 1.52 million. As of the previous 9 days, the stock’s Stochastic %D was 45.47%. Additionally, its Average True Range was 1.12.
During the past 100 days, Edgewise Therapeutics Inc’s (EWTX) raw stochastic average was set at 21.48%, which indicates a significant decrease from 30.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.17% in the past 14 days, which was lower than the 82.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.36, while its 200-day Moving Average is $24.61. Now, the first resistance to watch is $15.25. This is followed by the second major resistance level at $15.62. The third major resistance level sits at $15.91. If the price goes on to break the first support level at $14.59, it is likely to go to the next support level at $14.30. Now, if the price goes above the second support level, the third support stands at $13.93.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Key Stats
With a market capitalization of 1.56 billion, the company has a total of 105,200K Shares Outstanding. Currently, annual sales are 0 K while annual income is -133,810 K. The company’s previous quarter sales were 0 K while its latest quarter income was -40,800 K.
